[Remote] Rare Disease Sales Specialist - Des Moines IA at Axsome Therapeutics Inc

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Experience in pharmaceutical sales, preferably in rare disease or immunology
Strong understanding of the healthcare landscape, particularly within nephrology
Proven ability to build and maintain relationships with key healthcare professionals
Excellent communication, presentation, and interpersonal skills
Ability to analyze data and translate insights into actionable strategies
Goal-oriented and driven to achieve or exceed sales targets
Team-oriented with a collaborative mindset
Demonstrated resilience and determination

Responsibilities

Develop and execute a strategic plan to achieve or exceed sales targets within assigned territory
Identify, engage, and educate key healthcare professionals (HCPs)
Build and maintain relationships across community and academic centers
Analyze territory dynamics to uncover growth opportunities
Deliver clinical presentations on atacicept's mechanism of action, efficacy, safety, and patient benefits
Execute educational initiatives to enhance disease awareness and treatment understanding
Communicate complex clinical data in a clear and engaging way
Partner cross-functionally with Field Reimbursement, Medical Affairs, and Patient Support teams
Model Vera’s values of accountability, integrity, and compassion
Share best practices and insights to strengthen collective performance
Provide real-time feedback from the field to inform marketing and access strategies

Skills

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free